Solve Therapeutics has completed a $120 million unlabelled round as it advances a pair of antibody-drug conjugates (ADCs) for cancer that use its proprietary linker technology. San Diego-based Solve ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Mel Plaut Mel Plaut is a writer covering pets. They have tested hundreds of ...

Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...